Drug Trial Radar · NCT06016842
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
276
Planned (sponsor's estimate)
Start
Aug 31, 2023
Primary completion
May 31, 2029
Study completion May 31, 2029
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Aug 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to cirrhosis. PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done. This study will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment) and will last up to 3.5 years for each participant. The main aim of this study is to determine if elafibranor is better than placebo in preventing clinical outcome events showing disease worsening (including progression of disease leading to liver transplant or death). This study will also study the safety of long-term treatment with elafibranor, as well as the impact on symptoms such as itching and tiredness.
Conditions
- Primary Biliary Cholangitis (PBC)
Interventions
ElafibranorDrug
Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which elafibranor 80 mg tablet will be administered once daily
Matched 80 mg placeboOther
Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which matching placebo tablet will be administered once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survivalTime frame: From baseline until 4 weeks after the last dose of study intervention (maximum duration of 3.5 years)
Locations
198 sites in 28 countries. Site status is shown where the registry gives one.
Arizona Liver Health
Tucson, Arizona · Recruiting
Arkansas Diagnostic Center, PA
Little Rock, Arkansas · Terminated
Southern California Research Center
Coronado, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Withdrawn
GastroIntestinal BioSciences
Los Angeles, California · Active not recruiting
University of California Los Angeles
Los Angeles, California · Withdrawn
University of California Davis Medical Center
Sacramento, California · Recruiting
University of Colorado
Aurora, Colorado · Recruiting
Peak Gastroenterology Associates
Colorado Springs, Colorado · Recruiting
South Denver Gastroenterology, P.C.
Englewood, Colorado · Active not recruiting
Rocky Mountain Gastroenterology
Littleton, Colorado · Recruiting
University Of Miami School Of Medicine, Center For Liver Diseases
Miami, Florida · Recruiting
Bolanos Clinical Research
Pembroke Pines, Florida · Recruiting
International Center for Research
Tampa, Florida · Recruiting
University of Kansas Medical Center (KUMC) - University of Kansas Liver Center - Hepatology Clinic
Kansas City, Kansas · Not yet recruiting
Louisiana Research Center, LLC
Shreveport, Louisiana · Recruiting
University of Michigan Health System
Ann Arbor, Michigan · Recruiting
Huron Gastroenterology Associates - Center for Digestive Care
Ypsilanti, Michigan · Withdrawn
Mayo Clinic
Rochester, Minnesota · Recruiting
Southwest Gastroenterology Associates, PC (SWGA)
Albuquerque, New Mexico · Terminated
NYU Langone Gastroenterology and Hepatology Associates
New York, New York · Recruiting
University of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Recruiting
Gastroenterology Center of the Midsouth
Cordova, Tennessee · Recruiting
Texas Clinical Research Institute
Arlington, Texas · Recruiting
American Research Corporation
Austin, Texas · Recruiting
Rush University Medical Center - University Cardiovascular Surgeons
Dallas, Texas · Withdrawn
Liver Center of Texas
Dallas, Texas · Terminated
Methodist Transplant Physicians
Dallas, Texas · Recruiting
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas · Recruiting
Baylor Scott & White All Saints Medical Center - Forth Worth
Fort Worth, Texas · Withdrawn
Liver Associates of Texas
Houston, Texas · Recruiting
Houston Methodist Cancer Center
Houston, Texas · Active not recruiting
Gastro health & Nutrition
Katy, Texas · Terminated
American Research Corporation at The Texas Liver Institute
San Antonio, Texas · Recruiting
Starhope Liver Center, PA - Starhope Clinical Research, LLC
San Antonio, Texas · Recruiting
Impact Research Tx
Waco, Texas · Withdrawn
University of Virginia Medical Center
Charlottesville, Virginia · Recruiting
Bon Secours St. Mary's Hospital of Richmond, Inc
Richmond, Virginia · Recruiting
Virginia Commonwealth University Medical Center - West Hospital
Richmond, Virginia · Not yet recruiting
Showing 40 of 198 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.